Health AI Central
Share:
Peer-Reviewed Publication
EJNMMI Res2026;16(1)July 27, 2026Journal Article

Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels.

Ida Sonni1,2, Alexandra Gulpe3, Nicholas G Nickols4,5,6, Derace Schaffer7, Louis Montagut7,8, Gholam R Berenji1,2, Matthew B Rettig9,6,10
1Department of Radiological Sciences, University of California, Los Angeles, CA, USA.
2Department of Nuclear Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
3EXINI Diagnostics AB, Lund, Sweden. alexandra.gulpe@exini.com.
4Department of Radiation Oncology, University of California, Los Angeles, CA, USA.
5Department of Radiation Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
6Department of Urology, University of California, Los Angeles, CA, USA.
7EXINI Diagnostics AB, Lund, Sweden.
8Concord Academy, Concord, MA, USA.
9Department of Medicine, University of California, Los Angeles, CA, USA.
10Department of Medicine, Division of Hematology-Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
PubMed DOI

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.